“While the ‘drug+therapy’ approach may be therapeutically beneficial, the American healthcare system lacks the human capital — in the form of a sufficient number of trained mental health professionals — to deliver these therapies at scale. Even if the current shortage of mental health professionals were resolved, it is unclear that insurers would have the appetite to pay for a therapeutic approach requiring extensive psychological support for each patient.

In order to ensure equitable access to psychedelics, innovative solutions are required, such as the adoption of digital tools and in particular, virtual and augmented reality-mediated psychological support platforms.”

Access the full article here.